Regulatory B cells preferentially accumulate in tumor-draining lymph nodes and promote tumor growth

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ganti, Sheila N ^a   Albershardt, Tina C ^b   Iritani, Brian M ^a   Ruddell, Alanna ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; ANIMAL; B LYMPHOCYTE; C57BL MOUSE; CELL PROLIFERATION; FEMALE; IMMUNOLOGY; LYMPH NODE; LYMPHOCYTE SUBPOPULATION; MALE; NEOPLASM; PATHOLOGY; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; B-LYMPHOCYTES, REGULATORY; CELL PROLIFERATION; FEMALE; LYMPH NODES; LYMPHOCYTE SUBSETS; MALE; MICE, INBRED C57BL; NEOPLASMS; T-LYMPHOCYTES;

EID: 84937467969     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12255     Document Type: Article

References (27)

1. Ferris, R. L., Lotze, M. T., Leong, S. P., Hoon, D. S., Morton, D. L. Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. Clin Exp Metastasis 29, 729-736 (2012).
2. Harrell, M. I., Iritani, B. M., Ruddell, A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol 170, 774-786 (2007).
3. Ruddell, A., Harrell, M. I., Furuya, M., Kirschbaum, S. B., Iritani, B. M. B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma. Neoplasia 13, 748-757 (2011).
4. Shah, S. et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 117, 574-586 (2005).
5. Zhang, Y. et al. B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother 62, 87-99 (2013).
6. Evans, J. G. et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 178, 7868-7878 (2007).
7. Mizoguchi, A., Bhan, A. K. A case for regulatory B cells. J Immunol 176, 705-710 (2006).
8. Olkhanud, P. B. et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+ ) T cells to T-regulatory cells. Cancer Res 71, 3505-3515 (2011).
9. Spranger, S. et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+ ) T cells directly within the tumor microenvironment. J Immunother Cancer 2, 3 (2014).
10. DiLillo, D. J., Yanaba, K., Tedder, T. F. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 184, 4006-4016 (2010).
11. Balkwill, F., Montfort, A., Capasso, M. B regulatory cells in cancer. Trends Immunol 34, 169-173 (2013).
12. Park, C. et al. Lymph node B lymphocyte trafficking is constrained by anatomy and highly dependent upon chemoattractant desensitization. Blood 119, 978-989 (2012).
13. Klinger, A. et al. Cyclical expression of L-selectin (CD62L) by recirculating T cells. Int Immunol 21, 443-455 (2009).
14. Schioppa, T. et al. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci 108, 10662-10667 (2011).
15. Yanaba, K., Bouaziz, J. D., Matsushita, T., Tsubata, T., Tedder, T. F. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 182, 7459-7472 (2009).
16. Chen, X., Oppenheim, J. J., Howard, O. M. BALB/c mice have more CD4+ CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+ CD25-responder T cells than C57BL/6 mice. Journal of leukocyte biology 78, 114-121 (2005).
17. Fu, H. et al. Self-recognition of the endothelium enables regulatory T-cell trafficking and defines the kinetics of immune regulation. Nature communications 5, 3436 (2014).
18. Swartz, M. A. Immunomodulatory roles of lymphatic vessels in cancer progression. Cancer Immunol Res 2, 701-707 (2014).
19. Curran, M., Montalvo, W., Yagita, H., Allison, J. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci 107, 4275-4280 (2010).
20. Baird, J. R. et al. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated toxoplasma gondii protects against rechallenge. J Immunol 190, 469-478 (2012).
21. Devaud, C. et al. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Molecular therapy : the journal of the American Society of Gene Therapy 22, 18-27 (2014).
22. Lund, A. W. et al. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep 1, 191-199 (2012).
23. Tewalt, E. F. et al. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood 120, 4772-4782 (2012).
24. Andreu, P. et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17, 121-134 (2010).
25. Wong, S. C. et al. Macrophage polarization to a unique phenotype driven by B cells. Eur J Immunol 40, 2296-2307 (2010).
26. Lores, B., Garcia-Estevez, J. M., Arias, C. Lymph nodes and human tumors (review). Int J Mol Med 1, 729-733 (1998).
27. Vidal-Rubio, B., Sanchez-Carril, M., Oliver-Morales, J., Gonzalez-Femandez, A., Gambon-Deza, F. Changes in human lymphocyte subpopulations in tonsils and regional lymph nodes of human head and neck squamous carcinoma compared to control lymph nodes. BMC Immunol 2, 2 (2001).